Back to search results

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Basal Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California, Irvine, Irvine, California, United States

    Contact: Study coordinator (Mehir Tharani) · ucstudy@uci.edu · 877-827-8839

  • University of California, San Diego Moores Cancer Center, La Jolla, California, United States

    Contact: Study coordinator (Catherine O'Neil) · CancerCTO@health.ucsd.edu · 858 822 5354
    Contact: Principal Investigator (Soo Park, MD)

  • University of California, San Francisco, San Francisco, California, United States

    Contact: Study coordinator (Sonia Contreras Martinez) · Sonia.ContrerasMartinez@ucsd.edu · (415) 714-4484
    Contact: Principal Investigator (Adil Daud, MD)
Study leads

  • Soo Park, MD

    Principal Investigator

    UC San Diego Health - Moores Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)